AR127006A1 - UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc - Google Patents
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN FcInfo
- Publication number
- AR127006A1 AR127006A1 ARP220102429A ARP220102429A AR127006A1 AR 127006 A1 AR127006 A1 AR 127006A1 AR P220102429 A ARP220102429 A AR P220102429A AR P220102429 A ARP220102429 A AR P220102429A AR 127006 A1 AR127006 A1 AR 127006A1
- Authority
- AR
- Argentina
- Prior art keywords
- sample
- peptides
- quantifying
- liquid chromatography
- antibodies
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 12
- 239000000523 sample Substances 0.000 abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 9
- 229940126534 drug product Drugs 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000005040 ion trap Methods 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- 238000004811 liquid chromatography Methods 0.000 abstract 3
- 238000001802 infusion Methods 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
Abstract
Se proporcionan métodos sin cromatografía líquida para cuantificar una proteína diana en una muestra. Una forma de realización proporciona un método sin cromatografía líquida para cuantificar anticuerpos diana en una muestra que incluye las etapas de agregar a la muestra un anticuerpo estándar interno etiquetado, digerir los anticuerpos en la muestra para producir péptidos, fraccionar los péptidos; y cuantificar los anticuerpos diana mediante el uso de un sistema MS2 de infusión directa que contiene una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, en donde el método no comprende cromatografía líquida. Reivindicación 1: Un método sin cromatografía líquida para cuantificar anticuerpos diana en una muestra que comprende: agregar a la muestra un anticuerpo estándar interno etiquetado; digerir los anticuerpos de la muestra para producir péptidos; fraccionar los péptidos; y cuantificar los anticuerpos diana mediante el uso de un sistema MS2 de infusión directa que contiene una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, en donde el método no comprende cromatografía líquida. Reivindicación 9: Un método para cuantificar un producto de fármaco de proteína en una muestra biológica que comprende: agregar a la muestra una cantidad conocida de un péptido sustituto etiquetado con masa pesada que tiene una secuencia de aminoácidos de acuerdo con SEQ ID Nº 1; digerir el producto de fármaco de proteína de la muestra en péptidos; fraccionar los péptidos en condiciones que retengan péptidos que tengan una secuencia de aminoácidos de acuerdo con la SEQ ID Nº 1; analizar la muestra que contiene los péptidos con producto de fármaco de proteína y los péptidos sustitutos para la presencia del péptido que tiene una secuencia de aminoácido de acuerdo con SEQ ID Nº 1 mediante el uso de un sistema MS2 para calibrar el sistema, en donde el sistema MS2 comprende una o más trampas de iones y dos o más filtros de masas cuadripolares y un ionizador de electropulverización, y cuantificar la cantidad de producto de fármaco de proteína presente en la muestra en función de la presencia del péptido, en donde el método no utiliza la cromatografía líquida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241593P | 2021-09-08 | 2021-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127006A1 true AR127006A1 (es) | 2023-12-06 |
Family
ID=83995567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102429A AR127006A1 (es) | 2021-09-08 | 2022-09-08 | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230077710A1 (es) |
| AR (1) | AR127006A1 (es) |
| TW (1) | TW202326138A (es) |
| WO (1) | WO2023039457A1 (es) |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PT2374818E (pt) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| PT2975051T (pt) | 2009-06-26 | 2021-05-04 | Regeneron Pharma | Anticorpos biespecíficos rapidamente isolados com formato de imunoglobulina nativa |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| ES2567276T3 (es) * | 2011-05-12 | 2016-04-21 | Genentech, Inc. | Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| US9402898B2 (en) | 2012-01-23 | 2016-08-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| AR092098A1 (es) | 2012-08-13 | 2015-03-25 | Regeneron Pharma | ANTICUERPOS ANTI-PCSK9 CON CARACTERISTICAS DE UNION DEPENDIENTES DEL pH |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−３３拮抗薬とその使用法 |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015138460A1 (en) | 2014-03-11 | 2015-09-17 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibodies and uses thereof |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MA51519A (fr) | 2014-05-05 | 2020-11-11 | Regeneron Pharma | Animaux c5 et c3 humanisés |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| WO2016044337A1 (en) | 2014-09-16 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| AU2020397865C1 (en) * | 2019-12-06 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| EP4162250A1 (en) * | 2020-06-09 | 2023-04-12 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies |
-
2022
- 2022-09-08 AR ARP220102429A patent/AR127006A1/es unknown
- 2022-09-08 TW TW111134041A patent/TW202326138A/zh unknown
- 2022-09-08 WO PCT/US2022/076089 patent/WO2023039457A1/en unknown
- 2022-09-08 US US17/930,471 patent/US20230077710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023039457A1 (en) | 2023-03-16 |
| US20230077710A1 (en) | 2023-03-16 |
| TW202326138A (zh) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Füssl et al. | Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry | |
| Vidmar et al. | Protease cleavage site fingerprinting by label‐free in‐gel degradomics reveals pH‐dependent specificity switch of legumain | |
| Bendall et al. | An enhanced mass spectrometry approach reveals human embryonic stem cell growth factors in culture | |
| Steen et al. | Detection of tyrosine phosphorylated peptides by precursor ion scanning quadrupole TOF mass spectrometry in positive ion mode | |
| Wu et al. | Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system | |
| Kadek et al. | Aspartic protease nepenthesin-1 as a tool for digestion in hydrogen/deuterium exchange mass spectrometry | |
| Park et al. | Thermal denaturation: a useful technique in peptide mass mapping | |
| Buchberger et al. | Advances in mass spectrometric tools for probing neuropeptides | |
| Singh et al. | Characterization of protein cross-links via mass spectrometry and an open-modification search strategy | |
| Crowe et al. | Ubiquitin chain enrichment middle-down mass spectrometry enables characterization of branched ubiquitin chains in cellulo | |
| Kim et al. | In-source fragmentation and the sources of partially tryptic peptides in shotgun proteomics | |
| Calleri et al. | Trypsin-based monolithic bioreactor coupled on-line with LC/MS/MS system for protein digestion and variant identification in standard solutions and serum samples | |
| Delcourt et al. | Spatially-resolved top-down proteomics bridged to MALDI MS imaging reveals the molecular physiome of brain regions | |
| Wakabayashi et al. | Phosphoproteome analysis of formalin-fixed and paraffin-embedded tissue sections mounted on microscope slides | |
| JP2019507341A5 (es) | ||
| Ayoub et al. | Characterization of the N-terminal heterogeneities of monoclonal antibodies using in-gel charge derivatization of α-amines and LC-MS/MS | |
| Zhai et al. | Systematic research on the pretreatment of peptides for quantitative proteomics using a C 18 microcolumn | |
| KR20210153102A (ko) | 숙주세포 단백질의 확인 | |
| Zhu et al. | Absolute quantitation of host cell proteins in recombinant human monoclonal antibodies with an automated CZE‐ESI‐MS/MS system | |
| Huang et al. | Automatic disulfide bond assignment using a1 ion screening by mass spectrometry for structural characterization of protein pharmaceuticals | |
| Acquadro et al. | Human SOD1-G93A specific distribution evidenced in murine brain of a transgenic model for amyotrophic lateral sclerosis by MALDI imaging mass spectrometry | |
| Griffiths et al. | Mass spectral enhanced detection of Ubls using SWATH acquisition: MEDUSA—simultaneous quantification of SUMO and ubiquitin-derived isopeptides | |
| Resemann et al. | Rapid, automated characterization of disulfide bond scrambling and IgG2 isoform determination | |
| Rivera-Burgos et al. | Native protein proteolysis in an immobilized enzyme reactor as a function of temperature | |
| Boström et al. | Antibodies as means for selective mass spectrometry |